# First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory

> **NCT07177508** · — · COMPLETED · sponsor: **Nicola Irwin** · enrollment: 2355 (actual)

## Conditions studied

- Respiratory Syncytial Viral (RSV) Infection
- Respiratory Syncytial Virus Hospitalizations
- Respiratory Syncytial Virus Prevention

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07177508
- **Lead sponsor:** Nicola Irwin
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 2355 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07177508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07177508, "First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07177508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*